Management of Patients with Musculoskeletal Pain Syndrome during COVID-19 Pandemic

Objective of the Review: To discuss the efficiency and safety of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with low back pain (LBP), also during COVID-19 pandemic.

Key Points. Musculoskeletal pain syndromes, including LBP, are common; they affect the quality of patients’ life and result in huge medical bills. In a lot of post-COVID-19 patients, LBP appears for the first time or gets worse. Challenges in the management of such patients are caused by involvement of multiple organs and body systems, the need in taking numerous medications at once, which increases the risk of drug interaction. This overview describes the efficiency and safety of nimesulide in patients with low back pain. The use of NSAIDs in patients with COVID-19 is discussed. Beneficial effects and possible risks of nimesulide are analysed.

Conclusion. Management of patients with LBP during the COVID-19 pandemic requires thorough selection of an optimal therapy taking into account comorbidities and a high risk of drug-drug interactions. Nimesulide is a potent medication with a favourable safety and tolerability profile. It is advisable to use nimesulide in the management of patients with low back pain, including COVID-19 survivors. Safety of the therapy can be ensured by thorough drug selection taking into account comorbidities and risks of complications.

1. Karateev A.E., Lila A.M., Dydykina I.S., Kamchatnov P.R. et al. Personalization of the use of non-steroidal anti-inflammatory drugs for musculoskeletal diseases. Resolution on the results of the Meeting of Experts of December 13, 2017. Medical Council. 2018; 18: 76–84. (in Russian) DOI: 10.21518/2079-701X-2018-18-76-84

2. [Parfenov V.A., Yakhno N.N., Kukushkin M.L., Churyukanov M.V. et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics. 2018; 10(2): 4–11. (in Russiam). DOI: 10.14412/2074-2711-2018-2-4-11

3. Manchikanti L., Pampati V., Jha S.S., Sanapati M.R. et al. The impact of COVID-19 on interventional pain management practices is significant and long-lasting: an interventional pain management physician survey. Pain Physician. 2022; 25(2): 131–44.

4. Gharaei H., Diwan S. COVID-19 pandemic: implications on interventional pain practice: a narrative review. Pain Physician. 2020; 23(4S): S311–18.

5. Long Q.X., Tang X.J., Shi Q.L., Li Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020; 26(8): 1200–4. DOI: 10.1038/s41591-020-0965-6

6. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021; 27(4): 601–15. DOI: 10.1038/s41591-021-01283-z

7. Taquet M., Dercon Q., Luciano S., Geddes J.R. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021; 18(9): e1003773. DOI: 10.1371/journal.pmed.1003773

8. Bileviciute-Ljungar I., Norrefalk J.R., Borg K. Pain burden in postCOVID-19 syndrome following mild COVID-19 infection. J. Clin. Med. 2022; 11(3): 771. DOI: 10.3390/jcm11030771

9. Ali M., Bonna A.S., Sarkar A.S., Islam M.A. et al. SARS-CoV-2 infection is associated with low back pain: findings from a community-based case-control study. Int. J. Infect. Dis. 2022; 122: 144–51. DOI: 10.1016/j.ijid.2022.05.050

10. Ali M., Ahsan G.U., Hossain A. Prevalence and associated occupational factors of low back pain among the bank employees in Dhaka City. J. Occup. Health. 2020; 62(1): e12131. DOI: 10.1002/1348-9585.12131

11. Hartvigsen J., Hancock M.J., Kongsted A., Louw Q. et al. What low back pain is and why we need to pay attention. Lancet. 2018; 391(10137): 2356–67. DOI: 10.1016/S0140-6736(18)30480-X

12. Fatoye F., Gebrye T., Odeyemi I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol. Int. 2019; 39(4): 619–26. DOI: 10.1007/s00296-019-04273-0

13. Fiala K., Martens J., Abd-Elsayed A. Post-COVID pain syndromes. Curr. Pain Headache Rep. 2022; 26(5): 379–83. DOI: 10.1007/s11916-022-01038-6

14. Mokhtari T., Hassani F., Ghaffari N., Ebrahimi B. et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J. Mol. Histol. 2020; 51(6): 613–28. DOI: 10.1007/s10735-020-09915-3

15. Peiris S., Mesa H., Aysola A., Manivel J. et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021; 16(4): e0250708. DOI: 10.1371/journal.pone.0250708

16. Schiltenwolf M., Akbar M., Neubauer E., Gantz S. et al. The cognitive impact of chronic low back pain: positive effect of multidisciplinary pain therapy. Scand. J. Pain. 2017; 17: 273–8. DOI: 10.1016/j.sjpain.2017.07.019

17. Robertson D., Kumbhare D., Nolet P., Srbely J. et al. Associations between low back pain and depression and somatization in a Canadian emerging adult population. J. Can. Chiropr. Assoc. 2017; 61(2): 96–105.

18. Golovacheva V.A., Parfenov V.A. Treatment of musculoskeletal pain during COVID-19 pandemics. Clinical Pharmacology and Therapy. 2022; 31(1): 24–31 (in Russian). DOI: 10.32756/0869-5490-2022-1-24-31

19. Kamchatnov P.R., Evzelman M.A., Chugunov A.V. Peripheral nervous system disorders in COVID-19. Russian Medical Journal. 2021; 5: 30–4. (in Russian)

20. Robb C., Goepp M., Rossi A., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br. J. Pharmacol. 2020; 177(21): 4899–920. DOI: 10.1111/bph.15206

21. Reese J.T., Coleman B., Chan L., Blau H. et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohortstudy. Virol. J. 2022; 19(1): 84. DOI: 10.1186/s12985-022-01813-2

22. Wong A.Y., MacKenna B., Morton C.E., Schultze A. et al. Use of nonsteroidal anti-infammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann. Rheum. Dis. 2021; 80(7): 943–51. DOI: 10.1136/annrheumdis-2020-219517

23. Scalise M., Indiveri C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. SLAS Discov. 2020; 25(10): 1171–3. DOI: 10.1177/2472555220934421

24. Cava C., Bertoli G., Castiglioni I. In silico discovery of candidate drugs against Covid-19. Viruses. 2020; 12(4): 404. DOI: 10.3390/v12040404

25. Caiazzo E., Ialenti A., Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: what's going on? Eur. J. Pharmacol. 2019; 848: 105–11. DOI: 10.1016/j.ejphar.2019.01.044

26. Yang Z., Ji W., Li M., Qi Z. et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am. J. Transl. Res. 2019; 11(9): 6024–31.

27. Turkler C., Onat T., Yildirim E., Kaplan S. et al. Can the negative effects of ketamine abuse on female genital organs be prevented by nimesulide? An experimental study. Gen. Physiol. Biophys. 2019; 38(5): 427–34. DOI: 10.4149/gpb_2019023

28. Roberto G., Bartolini C., Rea F., Onder G. et al. Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. Eur. J. Clin. Pharmacol. 2018; 74(5): 637–43. DOI: 10.1007/s00228-018-2411-y

29. Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine. 2000; 25(12): 1579–85. DOI: 10.1097/00007632-200006150-00019

30. Shikhkerimov R.K. The use of nimesulide in the treatment of acute low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2016; 116(5): 28–32. (in Russian). DOI 10.17116/jnevro20161165128-32

31. Kamchatnov P.R., Kazakov A.Yu., Chugunov A.V. Efficacy and safety of nimesulide for the treatment of patients with dorsopathy. Consilium Medicum. 2016; 18(9): 116–21. (in Russian). DOI: 10.26442/2075-1753_2016.9.116-121

32. Zhou L., Pang X., Jiang J., Zhong D. et al. Nimesulide and 4'-hydroxynimesulide as bile acid transporters inhibitors are contributory factors for drug-induced cholestasis. Drug Metab. Dispos. 2017; 45(5): 441–8. DOI: 10.1124/dmd.116.074104

33. Kwon J., Kim S., Yoo H., Lee E. Nimesulide-induced hepatotoxicity: a systematic review and meta-analysis. PLoS One. 2019; 14(1): e0209264. DOI: 10.1371/journal.pone.0209264

34. Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin. Mol. Hepatol. 2020; 26(2): 142–54. DOI: 10.3350/cmh.2019.1003

35. Venegoni M., Da Cas R., Menniti-Ippolito F., Traversa G. et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann. Ist. Super Sanita. 2010; 46(2): 153–7. DOI: 10.4415/ANN_10_02_08

36. Süleyman H., Demircan B., Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep. 2007; 59(3): 247–58.

37. Koizumi S., Odashima M., Otaka M., Jin M. et al. Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the A2A adenosine receptor in rats. J. Gastroenterol. 2009; 44(5): 419–25. DOI: 10.1007/s00535-009-0028-8

38. Zak M.Y., Klymenko M.O., Iakovenko N.O., Grischenko G.V. Medicosocial value of osteoarthritis. secondary prevention and treatment of osteoarthritis in comorbidity with chronic gastritis. Wiad. Lek. 2019; 72(5 cz 2): 1064–7.

39. Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C. et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–46. DOI: 10.2165/11633470-000000000-00000

40. [Alekseeva L.I., Karateev A.E., Popkova T.V., Novikova D.S. et al. Efficacy and safety of nimesulide long term administration in patients with osteoarthritis: results of 12-months open controlled study DINAMO (long term administration of nimesulide in osteoarthritis multifactor assessment). Rheumatology Science and Practice. 2009; 4: 64–72. (in Russian)

41. Scheinberg M., Pott H. Jr, de Almeida Macêdo E., Bocchi de Oliveira M.F. et al. Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Drug Des. Devel. Ther. 2018; 12: 2775–83. DOI: 10.2147/DDDT.S172068

42. Fanelli A., Ghisi D., Aprile P.L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther. Adv. Drug Saf. 2017; 8: 173–82. DOI: 10.1177/2042098617690485

43. Masclee G.M.C., Straatman H., Arfè A., Castellsague J. et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS One. 2018; 13(11): e0204746. DOI: 10.1371/journal.pone.0204746

44. Schink T., Kollhorst B., Varas Lorenzo C., Arfè A. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: a multi-country European database study within the SOS Project. PLoS One. 2018; 13(9): e0203362. DOI: 10.1371/journal.pone.0203362

45. Rainsford K.D. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14(3–4): 120–37. DOI: 10.1007/s10787-006-1505-9

46. Singla A.K., Chawla M., Singh A. Nimesulide: some pharmaceutical and pharmacological aspects-an update. J. Pharm. Pharmacol. 2000; 52(5): 467–86. DOI: 10.1211/0022357001774255